申请人:Merck Sharp & Dohme Corp.
公开号:US07737295B2
公开(公告)日:2010-06-15
Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
公式I的化合物,包括该化合物的药学上可接受的盐,是CETP抑制剂,可用于提高HDL胆固醇,降低LDL胆固醇,并用于治疗或预防动脉粥样硬化。在公式1的化合物中,A1和A2分别是芳香环,5-6元杂环环,芳香环与杂环环融合,苯环与杂环环融合或环状烷基环。